Fig 7 and Table 5 show the results for this analysis, which reflect the genetically moderated effect of Clopidogrel treatment on the hazard of stroke per year, expressed as a percentage. The GMTE(1) estimate suggests that being a CYP2C19 LoF carrier (G = 1) increases the risk of stroke by 0.28% (p = 0.048) compared to those without the LoF variant (G = 0). This evidence concerns the gene CYP2C19 and stroke disorder.